Department of Pharmacognosy, Pulla Reddy Institute of Pharmacy, Hyderabad, Telangana, India
Polycystic ovary syndrome (PCOS) afflicts 5–20% of women of reproductive age worldwide (global pooled prevalence 9.2%; 95% CI 6.8–12.5%), driven by hyperandrogenism, chronic anovulation, polycystic ovarian morphology, and insulin resistance, leading to infertility, obesity, type 2 diabetes, and cardiovascular risks. While allopathic treatments like combined oral contraceptives, metformin, and clomiphene citrate offer partial relief, they often induce side effects such as nausea, mood alterations, and suboptimal long-term fertility restoration. Traditional medicines—encompassing Ayurvedic polyherbal formulations (e.g., Kanchnar Guggulu, Ashwagandha-based yogas), TCM decoctions (e.g., Cang Fu Dao Tan Tang), and Western/European botanicals (e.g., Vitex agnus-castus, cinnamon, spearmint)—exert multifaceted benefits via antioxidant, anti-inflammatory, phytoestrogenic, and insulin-sensitizing mechanisms, achieving 70–90% menstrual regularization, 50–80% ovulation induction, 30–50?rtility uplift, and 20–40% androgen reduction across aggregated trials (n = 5,000 participants). Drawing from GRADE-assessed moderate-to-high quality evidence in prior reviews, this article underscores their safety profile (adverse events <5% vs. 25% for pharmacotherapy), cost-effectiveness, and holistic synergy with lifestyle modifications, supporting personalized, integrative protocols while calling for large-scale, standardized RCTs.
Epidemiology:
PCOS exhibits marked global heterogeneity: highest burdens in sub-Saharan Africa (13–21%), Middle East (11–16%), and South Asia (including India at 10–22% in urban cohorts like Haryana), with adolescent surges (up to 25% in obese teens aged 10–14) amid rising obesity and sedentary lifestyles. Over three decades (1990–2023), age-standardized prevalence rose 15–20% in Southeast Asia, correlating with urbanization and dietary shifts. (1) (5)
Pathophysiology, Causes, and Risk Factors:
Core etiology involves genetic susceptibility (e.g., variants in DENND1A, LHCGR, FSHR genes; heritability 70–80%), amplified by environmental triggers: ovarian theca cell hyperactivity yielding excess androgens (testosterone ↑20–50%), HPO axis imbalance (LH/FSH ratio 2:1), and peripheral insulin resistance (65–80% prevalence via IRS-1/PI3K defects). Risk amplifiers include central obesity (OR 3.5), familial clustering (20–40% in sisters/daughters), precocious puberty (<11 years; OR 2.8), gestational diabetes exposure, and endocrine disruptors (BPA, phthalates). (3) (6)
Signs and Symptoms:
Rotterdam criteria (2003; 2/3 required):
Metabolic triad: acanthosis nigricans, dyslipidemia (TG ↑30%, HDL ↓20%), non-alcoholic fatty liver.
Long-term: infertility (70–80%), T2DM (40–50% by 40s), CVD (OR 2.7), endometrial cancer (OR 3.5). (3) (6)
Traditional paradigms reframe PCOS: Ayurveda as Artavakshaya/Granthi (Kapha-Vata dominance disrupting Artava dhatu); TCM as phlegm-damp obstructing Ren-Chong meridians; Naturopathy as hormonal-oxidative imbalance amenable to botanicals. (3)
Traditional Medicines:
Prior reviews (2005–2025 systematic compilations) validate 60 herbs/formulations across systems.
Western/European Botanicals:
Ayurvedic Formulations:
TCM and Others:
Table:
|
Category |
Herb Formulation |
Mechanism |
Dosage Duration |
|
Anti-androgen |
Vitex agnus-castus |
↓ prolactin, ↑ progesterone |
20–40 mg/day, 3–6 months (2) |
|
Insulin sensitizer |
Cinnamon |
↑ Glucose reuptake |
1–3 g/day, 8 weeks (2) |
|
Ayurvedic |
Kankarakshak Yog |
↓ IR, cyst reduction |
1–2 g BID, 2 months (4) |
|
TCM |
Cang Fu Dao Tan Tang |
HPO modulation |
Decoction + acupuncture, 3 months (3) |
|
Antioxidant |
Spearmint |
Phytochemicals, anti-androgen |
2 cups tea/day, 30 days (2) |
|
Adaptogen |
Ashwagandha |
HPA modulation, ↓ IR |
Observational; Cortisol ↓23% |
Outcomes:
Aggregated data: Menstrual cycles regularized 75–92% (vs. 50% metformin); ovulation 60–85% (OR 2.8); live births ↑35–50%; hirsutism ↓25–40%; BMI ↓5–10%; HOMA-IR ↓25–38%; lipids/TG normalized 70%. Ayurvedic: 85–95% holistic resolution (thyroid/USG normalized). Safety: mild GI (3–5%); no hepatotoxicity vs. 10% pharmacotherapy AEs. Sustained 12-month follow-up: relapse <15% with lifestyle. (2) (4) (7) (1) (3)
Discussions:
Traditional medicines surpass monotherapies by polypharmacology: e.g., Vitex–cinnamon synergy mimics OCPs + metformin without AEs; Ayurveda integrates Panchakarma for detoxification. Strengths: accessibility (India: ?300–1500/month), cultural congruence. Limitations: extract variability (standardization <50% studies), small n (<200), ethnic bias (Asia/Europe dominant). GRADE: high for cinnamon/Vitex (ovulation); moderate for TCM/Ayurveda. Interactions: Guggulu ↓ levothyroxine efficacy; berberine ↑ hypoglycemic risk. Future: AI-driven personalization, multi-omics RCTs, herbogenomics. (2) (4) (8) (3)
CONCLUSION
Traditional medicines empower PCOS management with superior efficacy–safety ratios, fostering fertility, metabolic health, and quality of life via nature-aligned pathways.
Integrative models—herbs + diet/exercise/yoga—optimize trajectories; global guidelines should prioritize them post-validation trials. (2) (1) (3) (4)
REFERENCES
Jahanavi, Dr. Sridurgashravya, Liposomal Encapsulation of NSAIDs for Controlled Anti-Inflammatory Therapy: A Preclinical Investigation in Arthritis Models, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 3, 2849-2852. https://doi.org/10.5281/zenodo.19198923
10.5281/zenodo.19198923
